[MDCO] The Medicines Company

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 35.16 Change: 0.59 (1.71%)
Ext. hours: Change: 0 (0%)

chart MDCO

Refresh chart

Strongest Trends Summary For MDCO

MDCO is in the medium-term up 7% above S&P in 1 month and up 83% in 6 months. In the long-term down -29% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -31.16% Sales Growth - Q/Q-33.76% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-0.97% ROE-2.21% ROI-1.29%
Current Ratio2.51 Quick Ratio2.15 Long Term Debt/Equity1.06 Debt Ratio0.35
Gross Margin62.22% Operating Margin-13.51% Net Profit Margin-3.29% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities397.92 M Cash From Investing Activities-119.38 M Cash From Operating Activities-41.03 M Gross Profit53.47 M
Net Profit-46.59 M Operating Profit-78.99 M Total Assets2.29 B Total Current Assets881.74 M
Total Current Liabilities351.44 M Total Debt562.73 M Total Liabilities1.29 B Total Revenue90.47 M
Technical Data
High 52 week40.94 Low 52 week17.26 Last close32.99 Last change-0.33%
RSI56.73 Average true range1.19 Beta0.98 Volume390.36 K
Simple moving average 20 days5.28% Simple moving average 50 days13.25% Simple moving average 200 days20.43%
Performance Data
Performance Week1.7% Performance Month19.83% Performance Quart33.19% Performance Half44.69%
Performance Year2.68% Performance Year-to-date72.36% Volatility daily2.03% Volatility weekly4.53%
Volatility monthly9.29% Volatility yearly32.17% Relative Volume137.41% Average Volume984.74 K
New High New Low

News

2019-06-18 09:58:01 | Alnylam Completes Enrollment in Phase III Study of Lumasiran

2019-06-18 08:06:33 | See what the IHS Markit Score report has to say about Medicines Co.

2019-06-17 19:15:51 | Did Hedge Funds Drop The Ball On Medicines Company MDCO?

2019-06-13 12:21:10 | Signal Says This Drug Stock Isn't Done Climbing

2019-06-13 08:02:51 | See what the IHS Markit Score report has to say about Medicines Co.

2019-06-06 15:28:07 | Alnylam Completes Rolling NDA Submission to FDA for Givosiran

2019-06-04 12:50:10 | These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming

2019-06-04 08:56:12 | Options Traders Expect Huge Moves in Medicines Company MDCO Stock

2019-06-04 08:02:27 | See what the IHS Markit Score report has to say about Medicines Co.

2019-06-03 16:48:08 | Alnylam Initiates Phase I Study on Hypertension Candidate

2019-06-03 06:43:04 | Notable Insider Buys This Past Week: Coty, Zillow and More

2019-06-01 08:03:22 | See what the IHS Markit Score report has to say about Medicines Co.

2019-05-27 10:21:00 | The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress

2019-05-25 09:31:01 | Medicines Co. MDCO Up 17.1% Since Last Earnings Report: Can It Continue?

2019-05-20 09:42:09 | Medicines Company Rallies On Positive LDL Cholesterol Study Results

2019-05-20 09:02:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2019-05-18 16:50:00 | New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years

2019-05-18 09:04:25 | What Kind Of Share Price Volatility Should You Expect For The Medicines Company NASDAQ:MDCO?

2019-05-14 11:45:31 | See what the IHS Markit Score report has to say about Medicines Co.

2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

2019-05-10 07:00:00 | The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions

2019-05-07 08:06:37 | See what the IHS Markit Score report has to say about Medicines Co.

2019-05-07 07:00:00 | The Medicines Company to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference

2019-05-02 13:20:07 | Did Hedge Funds Drop The Ball On The Medicines Company MDCO ?

2019-05-02 10:00:02 | Alnylam ALNY Reports Narrower-Than-Expected Loss in Q1

2019-05-01 10:03:35 | 4 ‘Strong Buy’ Stocks With Plenty Of Upside Ahead

2019-04-29 14:55:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2019-04-26 11:11:03 | Medicines Company MDCO Q1 Loss Narrows, Inclisiran in Focus

2019-04-26 08:35:39 | Medicines Co.: 1Q Earnings Snapshot

2019-04-26 07:29:54 | Medicines Co MDCO Q1 2019 Earnings Call Transcript

2019-04-26 01:36:07 | Edited Transcript of MDCO earnings conference call or presentation 25-Apr-19 12:30pm GMT

2019-04-25 07:00:00 | The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program

2019-04-18 07:00:00 | The Medicines Company to Announce First Quarter 2019 Financial Results on April 25

2019-04-17 10:32:02 | Medicines Co. MDCO May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-16 19:13:11 | Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

2019-04-15 16:49:08 | Alnylam ALNY Reports Phase III ENVISION Data on Givosiran

2019-04-12 08:49:12 | Implied Volatility Surging for Medicines Company MDCO Stock Options

2019-04-09 10:48:46 | See what the IHS Markit Score report has to say about Medicines Co.

2019-04-02 11:53:45 | See what the IHS Markit Score report has to say about Medicines Co.

2019-03-26 08:26:21 | See what the IHS Markit Score report has to say about Medicines Co.

2019-03-19 08:34:05 | See what the IHS Markit Score report has to say about Medicines Co.

2019-03-18 18:51:10 | Alnylam's ALNY Impressive Pipeline Drives Share Price

2019-03-15 16:24:16 | Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

2019-03-12 10:18:02 | Implied Volatility Surging for Medicines Company MDCO Stock Options

2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK

2019-03-10 19:14:42 | Insider Buys Of The Week: Arconic, CenturyLink, Hain Celestial and More

2019-03-08 16:32:33 | Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?

2019-03-08 14:51:34 | If You Had Bought Medicines NASDAQ:MDCO Stock A Year Ago, You’d Be Sitting On A 28% Loss, Today

2019-03-08 08:59:00 | Insider Buying Is Still Alive and Well at These 3 Companies

2019-03-08 02:08:55 | [$$] A disease in remission? New hope in the quest to cure HIV